↓ Skip to main content

Phase II trial of the regulatory T cell-depleting agent, denileukin diftitox, in patients with unresectable stage IV melanoma

Overview of attention for article published in BMC Cancer, December 2011
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (71st percentile)
  • Good Attention Score compared to outputs of the same age and source (70th percentile)

Mentioned by

policy
1 policy source
twitter
1 X user

Citations

dimensions_citation
63 Dimensions

Readers on

mendeley
61 Mendeley